Compare SUI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUI | JAZZ |
|---|---|---|
| Founded | 1975 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 16.1B |
| IPO Year | 1996 | 2007 |
| Metric | SUI | JAZZ |
|---|---|---|
| Price | $115.33 | $229.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 22 |
| Target Price | $135.21 | ★ $297.50 |
| AVG Volume (30 Days) | ★ 1.1M | 715.5K |
| Earning Date | 10-26-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ 1426.76 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $2,306,100,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $12.68 |
| Revenue Next Year | $1.96 | $5.34 |
| P/E Ratio | ★ N/A | $5,907.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $109.77 | $156.95 |
| 52 Week High | $137.85 | $266.38 |
| Indicator | SUI | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 48.42 |
| Support Level | $109.86 | $222.49 |
| Resistance Level | $124.16 | $244.93 |
| Average True Range (ATR) | 2.64 | 8.63 |
| MACD | -0.48 | 0.33 |
| Stochastic Oscillator | 15.82 | 36.41 |
Sun Communities is a residential REIT that focuses on owning manufactured housing and recreational vehicle communities. The company currently owns a portfolio of 455 properties, which includes 295 manufactured housing communities and 160 RV communities. Sun targets owning properties that are desirable as second homes or vacation properties, with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.